The Food and Drug Administration has approved the first pill specifically designed to treat postpartum depression, a common condition affecting mothers that can make it harder to bond with a new baby by causing severe despair, anxiety, shame, panic attacks, and suicidal thoughts. The drug, Zurzuvae, is designed to be taken once a day for two weeks after pregnancy—a much shorter period than currently deployed treatments, such as antidepressants or talk therapy, that are not specific to postpartum depression.